Seoul, South Korea, November 29, 2022 /PRNewswire/ — At the 2022 World Hair Research Congress (Melbourne, Australia), Yuyu Pharma has announced its intention to conduct clinical trials in the United States and Europe for its Dutasteride Tablet (“DUT”) for the treatment of androgenetic alopecia (“AGA”).
The DUT was developed to improve patient convenience and comfort by creating a smaller tablet size while maintaining the exact same 0.5mg dosage. There are plans to hold a pre-IND meeting with the US FDA and a scientific advisory meeting with Europe EMA next year.
Robert Yu, CEO of Yuyu Pharma, presents at the World Hair Research Congress.
Dutasteride inhibits both type I and type II 5-alpha reductase, which works to convert testosterone, a male hormone, into a DHT hormone. In scientific studies, excess DHT is believed to be the cause of hair loss.
Wonsang Robert YuCEO of Yuyu Pharma, said, “Dutasteride has been approved and is prescribed for patients with AGA in Korea and Japan. But it is not approved as a treatment for hair loss in the United States and Europe. We hope to experiment with getting the AGA on the label in the United States and Europe.”
About Yuyu Pharma
Yuyu Pharma (KRX: 000220) is a Korean pharmaceutical company founded in 1941 that manufactures and distributes pharmaceuticals, medical devices and dietary supplements. The company is also committed to developing innovative therapies in the fields of neurology, urology and ophthalmology. Yuyu’s mission is to improve the quality of life and well-being of all individuals by developing innovative health products and services.
SOURCE Yuyu Pharma
